Onsite Buprenorphine Treatment at Syringe Exchange Programs

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine

Criteria

Inclusion Criteria:

1. age ≥ 18 years

2. opioid use disorder

3. interest in buprenorphine treatment

4. motivation for opioid use disorder treatment

5. willingness to accept community health center referral

6. syringe exchange participant

Exclusion Criteria:

1. receiving opioid agonist treatment in the past 30 days (confirmed by New York Prescription Drug Monitoring Program);

2. inability to provide informed consent

3. unstable mental illness (e.g., suicidality, psychosis, etc.)

4. severe alcohol use disorder or benzodiazepine use disorder by the Diagnostic and Statistical Manual of Mental disorders, Fifth Edition (DSM-5) criteria

5. hypersensitivity to buprenorphine or naloxone.

6. pregnancy (confirmed via urine testing)